Prevalence of inflammatory bowel disease in patients with airways disease  by Raj, A.A. et al.
ARTICLE IN PRESS
Respiratory Medicine (2008) 102, 780–7850954-6111/$ - see fr
doi:10.1016/j.rmed.
Corresponding au
E-mail address: ASHORT REPORT
Prevalence of inﬂammatory bowel disease in patients
with airways disease
A.A. Raja,, S.S. Birringb, R. Greena, A. Grantc, J. de Caesteckerc, I.D. PavordaaDepartment of Respiratory Medicine, Institute for Lung Health, Glenﬁeld Hospital, Leicester, LE3 9PQ, UK
bDepartment of Respiratory Medicine, King’s College Hospital, London, UK
cDigestive Diseases Centre, University Hospitals of Leicester, UK
Received 7 May 2007; accepted 30 August 2007
Available online 5 March 2008KEYWORDS
Inﬂammatory bowel
disease;
Extra-intestinal
manifestations;
Airways disease;
Lymphocytic alveolitisont matter Crown
2007.08.014
thor. Tel.: +44 116
nita.Raj@uhl-tr.nSummary
Background: Case reports and case series have suggested an association between
inﬂammatory bowel disease (IBD) and airways disease, but there are no data
demonstrating a higher prevalence of IBD among patients with airways disease.
Furthermore, no consistent radiological, pulmonary or pathological abnormalities have
been demonstrated in patients with both conditions.
Aims: To determine the prevalence of IBD among patients with airways disease and to
evaluate clinical and pathophysiological features.
Methods: A retrospective analysis of outpatients with airways disease over a 10-year
period.
Results: IBD was four times more prevalent among patients with airways disease
compared with published local IBD prevalence [Odds Ratio 4.26, 95% CI 1.48, 11.71,
p ¼ 0.006; Crohn’s disease OR 5.96, 95% CI 1.94, 18.31, p ¼ 0.002 and ulcerative colitis OR
4.21, 95% CI 1.71, 10.41, p ¼ 0.001]. IBD was more frequent in all types of airways disease
except asthma; the association was particularly strong for conditions associated with
productive cough. All except 1 patient had established IBD before the onset of respiratory
symptoms. There were no obvious radiological differences between ulcerative colitis and
Crohn’s disease cases. There was a trend for a higher lymphocyte count (despite a
tendency to lower blood lymphocyte count) but lower sputum neutrophil count in patients
with Crohn’s disease compared with ulcerative colitis. There were no signiﬁcant
differences in physiological measurements of pulmonary function between the two types
of IBD.
Conclusion: Our ﬁndings support an association between airways disease and inﬂamma-
tory bowel disease, particularly non-asthmatic airways disease with productive cough.
Crown Copyright & 2007 Published by Elsevier Ltd. All rights reserved.Copyright & 2007 Published by Elsevier Ltd. All rights reserved.
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IBD prevalence in airways disease 781Diagnosis of IBD was conﬁrmed on the basis of a consistentIntroduction
25% of patients with inﬂammatory bowel disease (IBD) have
evidence of extra-intestinal manifestations.1 The best
known include pyoderma gangrenosum, erythema nodosum,
anterior uveitis, arthropathy, sacroileitis, ankylosing spon-
dylitis and primary sclerosing cholangitis. Lung involvement
in IBD was ﬁrst reported in 1976.2 Since then numerous case
reports and several case series have suggested an associa-
tion between IBD and a variety of bronchopulmonary
pathologies including: tracheal stenosis,3 chronic bronchitis
with and without suppuration,2,4 bronchiectasis,5–8 bronch-
iolitis 9 and asthma.10 Less commonly reported associations
include bronchiolitis obliterans organising pneumonia
(BOOP),8,11 granulomatous lung disease,12 pulmonary vascu-
litis,13 necrotic pulmonary nodules, drug-induced pneumo-
nitis and serositis.14
An intact colon and ongoing bowel inﬂammation are not
necessary for the pathogenesis of respiratory disease
associated with IBD, since there are reports of respiratory
disease developing after patients have undergone colect-
omy. In common with many other extra-intestinal manifes-
tations of IBD, the activity of the bowel disease is not
thought to be linked to the development and progression of
IBD-associated airways disease.
Most reported cases of airways disease are in patients
with ulcerative colitis. However, there has been no
systematic evaluation of IBD prevalence among patients
with airways disease and the apparent strong association
between ulcerative colitis and airways disease may arise
because ulcerative colitis is more prevalent than Crohn’s
disease.15 In support of this we have shown a threefold
increase in prevalence of cough, breathlessness and sputum
production among patients with either ulcerative colitis or
Crohn’s disease compared with controls.16 Moreover, sub-
clinical abnormalities of pulmonary function17–19 and airway
responsiveness20,21 are common in both conditions, although
lymphocytic alveolitis has been demonstrated only in
patients with Crohn’s disease without respiratory symp-
toms.22–24
The mechanisms for the pathogenesis of lung disease
associated with IBD are unknown. A better understanding of
the types of airways disease associated with IBD may aid
identiﬁcation of key factors involved in the pathogenesis.
We have, therefore, retrospectively identiﬁed IBD sufferers
among patients presenting to a respiratory clinic with
airways disease, in order to determine both prevalence
and to investigate patterns of airways disease.Methods
We reviewed all clinic letters of patients attending one
consultant’s (IDP) respiratory clinic between 1995 and 2005
to determine IBD prevalence among patients diagnosed with
airways disease. Numbers of patients seen were recorded
for all patterns of airway diseases. Clinical notes were
obtained and reviewed for all patients with a diagnosis of
IBD, history of bowel surgery (for IBD, or indication not
stated), use of 5-aminosalicylates or immunomodulators (if
indication not stated) recorded in the clinic letter.clinical picture with endoscopic and histological conﬁrma-
tion, or characteristic radiological appearances.
Airways disease was classiﬁed on the following grounds:
asthma: a consistent clinical picture with objective evi-
dence of variable outﬂow obstruction and/or airway hyper-
responsiveness (requiring at least one of the following:
415% rise in FEV1 20min after 200 mg inhaled salbutamol,
420% maximum PEF variability obtained from twice daily
PEF over 14 days, a positive methacholine provocation test
[PC20o8mg/ml]).25 COPD: a consistent clinical picture with
evidence of airﬂow obstruction (FEV1o70% of predicted and
FEV1/FVC o70%), and no signiﬁcant improvement in FEV1
after 200 mg inhaled salbutamol (o15%, or if FEV1o1 l,
o200ml improvement).26 Bronchiectasis: consistent clinical
picture with CTevidence of abnormal bronchial dilatation.27
Chronic bronchitis: productive cough for more than 3
months a year for more than 1 year in the absence of
radiological features of bronchiectasis and physiological
criteria for COPD.28 Chronic cough: persistent cough without
sputum for 4 8 weeks, with no evidence of asthma and no
response to proton pump inhibitors, nasal steroids or ACE
Inhibitor withdrawal.29 Bronchiolitis obliterans: a consistent
clinical picture with progressive airﬂow obstruction, CT
features of peribronchiolar inﬂammation and ﬁbrosis,
and/or ﬁbrosis of submucosal and peribronchiolar regions.
Duration of respiratory symptoms, absence or presence of
shortness of breath (SOB), wheeze, cough and sputum were
documented, as well as smoking history. The duration, type,
extent and where possible activity, using the Simple Clinical
Colitis Activity Index and the Crohn’s Disease Activity
Index,30,31 of IBD was sought. In addition, information on
surgery for IBD, type of surgery and length of time since
surgery, was also obtained.
Spirometry was performed with a Vitalograph spirometer
(Vitalograph, Buckinghamshire, UK). Lung function tests
were performed with a benchmark (PK Morgan, Chatham,
UK). Sputum induction was performed 10–30min after pre-
treatment with inhaled salbutamol 200 mg. However, 3%, 4%
and 5% saline was inhaled sequentially, each for 5min via an
ultrasonic nebuliser with an output of 0.9ml/min and
median mass diameter of 5.5mm (Medix, Harlow, UK). FEV1
was measured after each inhalation, a fall 4 20% of best
post-bronchodilator value resulted in discontinuation of the
procedure; a fall 410% but o20% resulted in the adminis-
tration of the same concentration of saline for the
subsequent inhalation.Analysis of data
Demographic characteristics were expressed as mean
7standard error of mean (SEM) values. Comparisons
between ulcerative colitis and Crohn’s disease patients;
for sputum and peripheral blood mean differential cell
counts, pulmonary function tests, mean duration of respira-
tory symptoms and IBD, were undertaken using unpaired
Student’s t-tests for parametric data w2 tests and Fisher’s
exact test were used for comparisons between Crohn’s
disease and ulcerative colitis patients for prevalence of
respiratory symptoms, smoking, medication use and abnor-
mal radiology results. Odds ratios were calculated to
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Table 1 Cases of IBD in respiratory clinic compared with expected cases [prevalence of UC 243 per 100 000: CD 130 per
100 000, IBD 396 per 100 000).15
Airways disease Patients
seen in
clinic
IBD cases (%) Odds ratio
observed/expected
95% Conﬁdence
interval of odds
ratio
p-Value
Chronic bronchitis 66
UC 1 6.39 0.85–47.98 0.000
CD 3 36.58 10.18–131.52 0.07
All IBD 4 (10) 16.07 3.92–65.76 0.006
Bronchiectasis 215
UC 4 7.88 2.71–22.91 0.000
CD 2 7.21 1.62–32.2 0.01
All IBD 7 (19) 8.38 2.43–28.89 0.001
Chronic cough 426
UC 6 5.94 2.41–14.60 0.000
CD 2 3.62 0.82–16.11 0.09
All IBD 8 (22) 4.76 1.43–15.90 0.011
COPD 588
UC 5 3.57 1.30–9.38 0.01
CD 4 5.26 1.71–16.19 0.04
All IBD 9 (24) 3.87 1.19–12.62 0.025
Asthma 893
UC 6 2.81 1.15–6.9 0.02
CD 2 1.74 0.39–7.65 0.47
All IBD 9 (24) 2.54 0.78–8.26 0.123
Total 2192
UC 22 4.21 1.71–10.41 0.001
CD 13 5.96 1.94–18.31 0.002
All IBD 37 4.26 1.48–11.71 0.006
UC, ulcerative disease; CD, Crohn’s disease.
A.A. Raj et al.782determine the ratio of IBD cases in the airways disease
population compared with the predicted number of cases in
a theoretical similar-sized general population cohort, using
published local IBD prevalence data15; this was calculated in
2002 from 15 general practices in the Trent region, with a
combined list size of 86 801; prevalence of IBD was 396 per
100 000, Crohn’s disease 130 per 100 000 and ulcerative
colitis 243 per 100 000. All tests were two-sided and a p
valueo0.05 was considered statistically signiﬁcant. All
analysis was performed using SPSS 12 for Windows.Results
Altogether, 2192 patients with airways disease were seen,
representing 79% of all respiratory patients seen. Forty-
eight had a diagnosis of IBD recorded in their clinic letter.
Eleven were excluded from subsequent analysis for the
following reasons: IBD not conﬁrmed by histology (n ¼ 2);
lung disease other than airways disease (n ¼ 5), including 1
case of pneumonitis secondary to mesalazine therapy; no
underlying chronic bronchopulmonary pathology after in-
vestigation (n ¼ 4: symptoms of breathlessness only, n ¼ 1;
acute respiratory tract infection, n ¼ 2; pneumonia, n ¼ 1).There were signiﬁcantly more cases of IBD in patients with
airways disease than would be expected in a similar sized
general population cohort, using local IBD prevalence data15
[OR 4.26, 95% CI 1.48, 11.71, p ¼ 0.006]. This was true for
both Crohn’s disease [OR 5.96, 95% CI 1.94, 18.31,
p ¼ 0.002] and ulcerative colitis [OR 4.21, 95% CI 1.71,
10.41, p ¼ 0.001]. IBD was more prevalent in all patterns
of airways disease except asthma; the association was
particularly strong with airways disease associated with
productive cough (Table 1). There were signiﬁcantly more
cases of ulcerative colitis than expected in all patterns of
airways disease, although this just failed to reach signiﬁ-
cance in chronic bronchitis (Table 1). Crohn’s disease
was more prevalent in COPD and bronchiectasis, just failing
to reach signiﬁcance in chronic bronchitis and chronic
cough.
Ulcerative colitis was the diagnosis in 62% of cases, whilst
32% had Crohn’s disease, and 6% had indeterminate colitis.
There were no signiﬁcant differences in baseline character-
istics between subjects with ulcerative colitis and Crohn’s
disease (Table 2). IBD diagnosis preceded onset of respira-
tory symptoms in all patients except 1 with Crohn’s disease.
A colectomy, predating the onset of respiratory symptoms
in all cases, had been performed in 24% of cases. There
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Table 2 Subject demographics.
UC CD
N (% female) 22 (59) 13 (54)
Age in years 61 (3) 60 (4)
Non-smokers n (%) 9 (45) 4 (31)
Ex-smokers n (%) 10 (50) 6 (46)
Current smokers n (%) 1 (5) 3 (23)
Duration of respiratory symptoms
in months
30 (10) 33 (6)
Length of IBD diagnosis in years 16 (2) 15 (3)
SOB n (%) 11 (65) 8 (62)
Wheeze n (%) 9 (56) 5 (38)
Cough n (%) 13 (76) 12 (92)
Sputum n (%) 7 (41) 9 (69)
Using azothioprine/6MP n (%) 5 (21) 1 (8)
On 5 ASA n (%) 15 (79) 6 (46)
Colectomy n (%) 5 (28) 4 (31)
On oral steroids for IBD at initial
consultation n (%)
0 (0) 2 (15)
Normal CT n (%) 1 (14) 3 (23)
Normal CXR n (%) 11 (73) 8 (62)
Values expressed as mean (SEM), except where stated.
Denominator varies according to number of patients with
relevant information documented.
IBD prevalence in airways disease 783were insufﬁcient clinical details at the initial respiratory
consultation to determine the Crohn’s Disease Activity Index
or the Simple Clinical Colitis Activity Index, but most
patients appeared to have clinically inactive or mild disease
at the time of consultation and did not relate respiratory
symptoms to IBD activity.
Eighteen patients underwent induced sputum as part of
their clinical work-up; 3 were unable to provide a sputum
sample despite induction. There were no statistically
signiﬁcant differences between patients with ulcerative
colitis and those with Crohn’s disease. However, there was a
non-signiﬁcant trend for a higher sputum lymphocyte
differential in patients with Crohn’s disease compared with
ulcerative colitis patients (Table 3). Crohn’s disease patients
also had a peripheral blood lymphocyte count at the lower
end of normal range, and lower than ulcerative colitis
subjects, although again statistical signiﬁcance was not
reached. There was no difference in use of Azathioprine,
which can induce lymphopenia, between the two groups.
There was a non-signiﬁcant trend for a lower sputum
neutrophil count in those with Crohn’s disease with no
differences in absolute sputum neutrophil count or periph-
eral blood neutrophil count (Table 3). Both groups had a
higher sputum eosinophil count than the normal range, but
there was no statistically signiﬁcant difference between the
groups.
Results of baseline spirometry were recorded in 33
patients and results of full pulmonary function tests in 11.
There was a trend for a lower FEF25–75 among patients with
Crohn’s disease compared with those with ulcerative colitis
(percentage predicted FEF 25–75 31% vs 65%, mean difference
34, 95% CI 6.7, 74, p ¼ 0.09), but there were no other
differences (Table 3).Discussion
We have shown a fourfold increased prevalence of IBD in our
cohort of patients with airways disease; prevalence of both
Crohn’s disease and ulcerative colitis was increased to a
similar extent, particularly in non-asthmatic airways dis-
ease. The prevalence of ulcerative colitis was higher in all
types of airways disease, whereas Crohn’s disease preva-
lence was greater in patients with airways disease asso-
ciated with productive cough. However, the small numbers
of patients involved make it difﬁcult to draw meaningful
conclusions about differences in patterns of airways disease
according to IBD type.
Whilst retrospective analyses are a less robust methodol-
ogy than population studies, our ﬁndings strengthen the case
for an association between IBD and airways disease, an
association previously based on evidence from case reports
and case series.2–14 Moreover, our ﬁndings are in keeping
with the predominance of non-asthmatic airways disease
with productive cough seen in the majority of case series.
However, further studies need to be conducted to determine
whether our ﬁndings can be replicated in population-based
studies. One weakness of our study is that adjustments for
age or smoking status were not made, as this information
was not available in either the airways disease population or
the local general population sample, although the age of
patients with IBD in both populations was comparable. It is
unlikely that age accounted for the difference in IBD
prevalence in the two populations, since the highest age-
speciﬁc incidence rates of ulcerative colitis is 30–39 years
and 20 29 years for Crohn’s disease 32–34 and almost all of
our patients with IBD and airways disease had IBD of long
duration. Similarly, differences in smoking prevalence
between the 2 populations is unlikely to have accounted
for the increased prevalence of ulcerative colitis amongst
the population with airways disease since there is evidence
that smoking protects against the development of ulcerative
colitis, and the relative risk of ulcerative colitis occurring in
non-smokers versus smokers is 2.6.35 Smoking is associated
with an increased risk of Crohn’s disease, so we cannot
exclude the possibility that the excess of Crohn’s disease
cases in our population with airways disease could be
attributed to smoking. However, the proportion of current
smokers in our cohort of patients with IBD and airways
disease was very similar to that in the IBD patients in our
general population cohort.
It is plausible that the increased IBD prevalence seen in
our patients with airways disease results from patients with
multiple diseases being referred more frequently to sec-
ondary care than those with just one disease. However,
similarities between prevalence of respiratory symptoms in
our earlier survey16 and the current ﬁndings increase
conﬁdence that the association is real. It is more likely that
the prevalence of IBD amongst our airways disease popula-
tion has been underestimated as a limitation of our study
was that the diagnosis of IBD was not systematically
gathered and may not be reported by patients, particularly
if their disease was of long duration and had been inactive
for some time. Furthermore, our methodology meant that
we were unable to identify patients no longer under active
respiratory follow-up, who may subsequently have been
diagnosed with IBD.
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Table 3 Induced sputum and lung function results for all IBD and airways disease patients and by IBD type.
IBD UC Number CD Number
Induced sputum: differential white cell count
Neutrophils Normal 30.6 range (0–74.2) 67.1 (7.3) 76.9 (9.3) 7 58.6 (10.5) 8
Eosinophils Normal 0.15 range (0.2–0.6) 2.4 (1.7) 3.69 (3.50) 7 1.10 (0.38) 7
Lymphocytes Normal 1 range (0.3–2.2) 2.2 (1.4) 0.51 (0.15) 7 3.76 (2.47) 8
Induced sputum: Absolute cell count ( 104/g)
Neutrophils 587 (154) 613 (227) 6 556 (228) 5
Eosinophils 10.4 (5.7) 11.7 (10.4) 6 8.8 (3.9) 5
Lymphocytes 8.9 (4.1) 3.4 (2) 6 15.5 (8.3) 5
Total cell count ( 106/mg) 7.0 (1.6) 7.1 (2.3) 6 6.9 (2.6) 5
Lung function
FEV1 (% predicted) 75 (4.7) 81 (6.4) 20 67 (6.3) 12
FEV1/FVC Ratio % 68 (2.8) 70 (3.7) 20 67 (4.4) 12
RV (% predicted) 112 (9.7) 103 (8.8) 8 129 (20.1) 5
TLC (% predicted) 92 (4.4) 91 (4.6) 8 95 (9.6) 5
RV/TLC (% predicted) 119 (7.3) 110 (8.4) 8 134 (11.5) 5
KCO (% predicted) 106 (9.9) 115 (11.9) 8 92 (16.7) 5
FEF25–75 (% predicted) 49 (10.2) 65 (13.6) 6 31 (11.6) 5
Exhaled nitric oxide 11.9 (3.1) 14.85 (4.37) 11 7.37 (3.79) 7
Values expressed as mean (SEM).
A.A. Raj et al.784Our results do not demonstrate any statistically signiﬁcant
difference in pulmonary function or pattern of airway
inﬂammation between patients with ulcerative colitis and
Crohn’s disease. However, the study was not powered to
detect such a difference and numbers of patients completing
induced-sputum and full-lung function tests were small (15
and 11, respectively). Moreover, as this was a retrospective
study there were neither healthy controls, non-IBD patients
with the same airways disease, nor IBD patients without
respiratory symptoms for comparison. Nonetheless, trends in
the pattern of airway inﬂammation and lung function may
suggest different mechanisms for the pathogenesis of airways
disease in these two conditions. We had insufﬁcient informa-
tion on the extent of IBD and its activity to allow meaningful
conclusions to be drawn on the relationship between bowel
activity and airway disease. The different patterns of airways
disease associated with different types of IBD, how they
compare with patients with the same airways disease but
without IBD and the relationship between activity of IBD, and
airways disease have to be investigated further in an
appropriately designed and powered prospective study.
In summary, we have found a signiﬁcantly higher
prevalence of both ulcerative colitis and Crohn’s disease in
our cohort of patients with airways disease compared with
the expected population prevalence. The association was
strongest in airways disease associated with productive
cough and in patients with ulcerative colitis. The mechan-
isms for development of airways disease may differ between
ulcerative colitis and Crohn’s disease.
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